Short summary

Our recent article in Cancer Imaging addresses cabazitaxel-induced ureteritis in mCRPC patients, revealing that 10% showed symptoms like hematuria and hydronephrosis. We propose management strategies that could improve patient outcomes.

Rationale

One of the main and effective therapy choices for patients with metastatic castration-resistant prostate cancer (mCRPC) is cabazitaxel (CBZ). Cystitis and hematuria are among the most significant non-hematological adverse events associated with CBZ treatment. But because the prevalence of CBZ-induced ureteritis has not been thoroughly studied, this case series investigation was carried out to emphasize the condition's clinical relevance and potential treatment alternatives.

Description of the cohort

Between June 2014 and May 2024, 354 patients diagnosed with mCRPC were treated with CBZ at the Department of Oncology, Vejle Hospital.

Data and biological material

A total of 36 patients (10%) exhibited ureteritis-like symptoms, presenting with discomfort in the pelvis, lower abdomen, or flanks, with or without hematuria. Radiological evidence of ureter changes was present in 29 out of 36 individuals (80%), along with hydronephrosis/hydroureter in some patients. Prior to therapy with CBZ, radiation to the pelvis or lower abdomen was documented in 7 out of 36 patients (19%). Various analgesics and dosage modifications were considered for the therapy of CBZ-induced ureteritis, with treatment discontinuation yielding the most favorable results.

Collaborating researchers and departments

Department of Urology , Lillebaelt Hospital, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark

Department of Urology, Esbjerg and Grindsted Hospital, University Hospital of Southern Denmark, Esbjerg, Denmark

Department of Radiology, Lillebaelt Hospital, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark

Publications associated with the project

Cabazitaxel-induced ureteritis in metastatic castration-resistant prostate cancer patients: a single center case series 2014-2024.